HTML

Australia’s pharmaceutical cost sharing policy: reducing waste or affordability?
Evan Doran and Jane Robertson — Aust Health Rev 2009; 33 (2): 231-240.

HTML

The impact of copayments and safety nets on PBS expenditure
Kim Sweeny — Aust Health Rev 2009; 33 (2): 215-230.

HTML

High prices for generics in Australia — more competition might help
Liliana Bulfone — Aust Health Rev 2009; 33 (2): 200-214.

HTML

PBS reform — a missed opportunity?
Rebecca de Boer — Aust Health Rev 2009; 33 (2): 176-185.

HTML

It’s not the evidence, it’s the way you use it: is clinical practice being tyrannised by evidence?
Kathy Stiller — Aust Health Rev 2008; 32 (2): 204-207.

HTML

The subsidy of pharmaceuticals in Australia: processes and challenges
Lloyd Sansom — Aust Health Rev 2004; 28 (2): 194-205.

HTML

Some drugs more equal than others: pseudo-generics and commercial practice
Andrew J Probyn — Aust Health Rev 2004; 28 (2): 207-217.

HTML

Patents, pills and politics: the Australia–United States Free Trade Agreement and the Pharmaceutical Benefits Scheme
Ken Harvey — Aust Health Rev 2004; 28 (2): 218-226.

HTML

Community pharmacy in Australia
Shalom I Benrimoj and Michael S Frommer — Aust Health Rev 2004; 28 (2): 238-246.

HTML

Private health insurance and the Pharmaceutical Benefits Scheme: how effective has recent government policy been?
Jeff R J Richardson and Leonie Segal — Aust Health Rev 2004; 28 (1): 34-47.